Research programme: HIV integrase inhibitors - Merck

Drug Profile

Research programme: HIV integrase inhibitors - Merck

Alternative Names: L-870812; L-900564; MK-2048

Latest Information Update: 29 Aug 2011

Price : $50

At a glance

  • Originator Merck & Co
  • Class Naphthyridines; Pyrimidinones
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 29 Aug 2011 No development reported - Preclinical for HIV infections in USA (PO)
  • 10 Apr 2008 Interim pharmacokinetics and pharmacodynamics data from a preclinical study in HIV Infections presented at the the 235th American Chemical Society National Meeting (235th-ACS-2008)
  • 14 Mar 2007 Data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI-2007) added to the Viral Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top